<DOC>
	<DOCNO>NCT02654860</DOCNO>
	<brief_summary>The objective study investigate efficacy safety single intrathecal injection paracetamol , administer 3 dos 3 active treatment group , compare placebo solution , post-operative analgesia hip replacement surgery perform spinal anaesthesia . Patients scheduled hip replacement surgery randomise 4 treatment group ( 15 patient per group ) receive either one 3 single dos paracetamol 3 % ( D1 : 60 mg , D2 : 90 mg , D3 : 120 mg ) placebo solution ( P : saline solution ) intrathecal ( IT ) injection . Immediately paracetamol placebo IT administration , patient receive single IT dose Hyperbaric Bupivacaine HCl 0.5 % ( 12.5 mg ≤ 160 cm-tall patient 15 mg &gt; 160 cm-tall patient ) . The time interval paracetamol IT bupivacaine IT administration exceed 2 min . The study include screen phase ( Visit 1 , Days -21/1 ) , treatment phase ( paracetamol IT administration , anaesthesia surgical procedure : Visit 2 , Day 1 ) follow-up phase include observation period ( Visit 3 , Day 1 surgery discharge , final visit ( discharge ) follow-up ( day 6±1 ) . Pain rest assess screen visit 2 baseline ( 0 h ) , 1 , 2 , 3 , 6 , 9 , 12 , 15 , 18 , 21 , 24 , 27 , 30 , 33 , 36 , 39 , 42 , 45 48 h anaesthetic IT injection discharge , use 0-100 mm VAS .</brief_summary>
	<brief_title>Dose-finding Study Intrathecal Paracetamol Administered Immediately Before Spinal Anaesthesia</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Bupivacaine</mesh_term>
	<mesh_term>Morphine</mesh_term>
	<mesh_term>Acetaminophen</mesh_term>
	<criteria>Informed consent : sign write informed consent inclusion study Sex , age surgery : male/female 1880 year ( inclusive ) old patient , schedule hip replacement surgery , anticipate need postoperative narcotic analgesia , adequate i.v . access anticipate hospital stay &gt; 48 hour . Body Mass Index ( BMI ) : 18 34 kg/m2 inclusive ASA physical status : IIII Full comprehension : ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate investigator comply requirement entire study Physical finding : clinically significant abnormal physical finding could interfere objective study . Contraindications spinal anaesthesia . History neuromuscular disease low extremity ASA physical status : IVV Further anaesthesia : patient expect require anaesthesia Pain assessment : anticipated unable make reliable selfreport pain intensity Allergy : ascertain presumptive hypersensitivity active principle ( paracetamol and/or amide type anaesthetic ) and/or formulation ' ingredient related drug , opioids , nonsteroidal antiinflammatory drug ; history anaphylaxis drug allergic reaction general , investigator considers could affect outcome study Diseases : significant history renal , hepatic , gastrointestinal , cardiovascular , respiratory , skin , haematological , endocrine neurological disease may interfere aim study ; ascertain psychiatric neurological disease , sepsis , blood coagulation disorder , severe cardiopulmonary disease , thyroid disease , diabetes , neuropathy , history evidence asthma heart failure . History severe head trauma require hospitalisation , intracranial surgery stroke within previous 30 day , history intracerebral arteriovenous malformation , cerebral aneurism CNS mass lesion . Liver function : Impaired liver function ( transaminases &gt; twice upper limit ) Renal function : Renal dysfunction ( creatinine &gt; 2.0 mg/dL ) Investigative drug study : participation evaluation investigational product 3 month study , calculate first day month follow last visit previous study Drug , alcohol : history drug alcohol abuse . Preexisting dependence narcotic know tolerance opioids Pregnancy lactation : positive pregnancy test screening ( applicable ) , pregnant lactate woman [ The pregnancy test perform fertile woman woman 55 year old , proven menopause ( available laboratory test confirming menopause surgically sterilise ) ] Chronic pain syndrome : patient chronic pain syndrome ( take opioids , anticonvulsant agent chronic analgesic therapy ) . Medications : medication know interfere extent spinal block 2 week start study . Paracetamol formulation , investigational product , 1 week start study study . Hormonal contraceptives female allow .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>